Vazalore generic
Vazalore is an oral drug owned by Plx Pharma and authorized for market use from 14 January, 2013. This drug uses aspirin as its active ingredient and is available in a capsule form.
When will Vazalore generic be available?
Vazalore's generic versions could potentially hit the market after 29 September, 2032. This release date accounts for the expiry of its last patent, namely US9216150, which expires on 29 September, 2032.
Vazalore uses
Vazalore, because it contains aspirin, serves a multitude of uses. It can be employed for the treatment and prevention of cardiovascular disease. It also provides temporary relief from minor aches and pains and reduces fever. Vazalore is also used as a method of targeting the release of a non-steroidal anti-inflammatory drug (NSAID) to the small intestine when administered orally.
Vazalore patent expiration
Vazalore has a total of 6 patents, with the last one, US9216150 expiring on 29 September, 2032. The drug's patents aim to protect the specific formulation of the medication, focusing on the pH-dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract. Once the final patents expire, one can expect the release Vazalore generic. Below are the details of the patents: